Skip to main content
SpringerLink
Log in

FDG-PET and PET/CT in Pancreatic Cancer

  • Chapter
Diseases of the Pancreas

  • 2213 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Warshaw AL, Castillo CFD (1992) Pancreatic carcinoma. New Engl J Med 326:455–465

    Article  PubMed  CAS  Google Scholar 

  2. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2005) Cancer statistics, 2005. CA Cancer J Clin 53:5–26

    Article  Google Scholar 

  3. Andren-Sandberg A, Neoptolemos JP (2002) Resection for pancreatic cancer in the new millennium. Pancreatology 2:431–439

    Article  PubMed  Google Scholar 

  4. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP (1995) Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 82:111–115

    Article  PubMed  CAS  Google Scholar 

  5. Shore S, Raraty MG, Ghaneh P, Neoptolemos JP (2003) chemotherapy for pancreatic cancer. Aliment Pharmacol Ther 18:1049–1069

    Article  PubMed  CAS  Google Scholar 

  6. Maringhini A, Ciambra M, Raimondo M, Baccelliere P, Grasso R, Dardanoni G, et al (1993) Clinical presentation and ultrasonography in the diagnosis of pancreatic cancer. Pancreas 8:146–150

    Article  PubMed  CAS  Google Scholar 

  7. Reske SN, Grillenberger KG, Glatting G, Port M, Hildebrandt M, Gansauge F, et al (1997) Overexpression of glucose transporter 1 and increased FDG uptake in pancreatic carcinoma. J Nucl Med 38:1344–1348

    PubMed  CAS  Google Scholar 

  8. Zimny M, Fass J (2000) Fluorodeoxyglucose positron emission tomography and the prognosis of pancreatic carcinoma. Scand J Gastroenterol 35:883–888

    Article  PubMed  CAS  Google Scholar 

  9. Diederichs CG, Staib L, Vogel J, Glasbrenner B, Glatting G, Brambs HJ, et al (2000) Values and limitations of 18F-fluoro-deoxyglucose-positron-emission tomography with preoperative evaluation of patients with pancreatic masses. Pancreas 20:109–116

    Article  PubMed  CAS  Google Scholar 

  10. Stollfuss JC, Glatting G, Friess H, Kocher F, Berger HG, Reske SN (1995) 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreatic cancer: value of quantitative image interpretation. Radiology 195:339–344

    PubMed  CAS  Google Scholar 

  11. Fröhlich A, Diederichs C, Staib L, Beger H, Reske S (1997) FDG-PET in the detection of pancreatic cancer liver metastases. J Nucl Med 38:145P

    Google Scholar 

  12. Fröhlich A, Diederichs CG, Staib L, Vogel J, Beger HG, Reske SN (1999) Detection of liver metastases from pancreatic cancer using FDG PET. J Nucl Med 40:250–255

    PubMed  Google Scholar 

  13. Friess H, Langhans J, Ebert M, Beger H, Stollfuß J, Reske S, et al (1995) Diagnosis of pancreatic cancer by 2[18-F]-fluoro-deoxy-D-glucose positron emission tomography. Gut 36:771–777

    Article  PubMed  CAS  Google Scholar 

  14. Bares R, Klever P, Hauptmann S, Hellwig D, Fass J, Cremerius U, et al (1994) F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 192:79–86

    PubMed  CAS  Google Scholar 

  15. Zimny M, Bares R, Fass J, Adam G, Cremerius U, Dohmen B, et al (1997) Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med 24:678–682

    PubMed  CAS  Google Scholar 

  16. Delbeke D, Rose M (1999) Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med 40:1784–1791

    PubMed  CAS  Google Scholar 

  17. Ho CL, Dehdashti F, Griffeth LK, Buse PE, Balfe DM, Siegel BA (1996) FDG-PET evaluation of indeterminate pancreatic masses. J Comp Assist Tomogr 20:363–369

    Article  CAS  Google Scholar 

  18. Orlando LA, Kulasingam SL (2004) Meta-analysis: the detection of pancreatic malignancy with positron emission tomography. Aliment Pharmacol Ther 20:1063–1070

    Article  PubMed  CAS  Google Scholar 

  19. Diederichs C, Staib L, Glatting G, Beger H, Reske S (1998) FDG-PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med 39:1030–1033

    PubMed  CAS  Google Scholar 

  20. Bares R, Klever P, Hellwig D, Hauptmann S, Fass J, Hambuechen U, et al (1993) Pancreatic cancer detected by positron emission tomography with 18-F-labelled deoxyglucose: method and first results. Nucl Med Commun 14:596–601

    Article  PubMed  CAS  Google Scholar 

  21. Sendler A, Avril N (2000) Preoperative evaluation of pancreatic masses with positron emission tomography using 18Ffluorodeoxyglucose: diagnostic limitations. World J Surg 24:1121–1129

    Article  PubMed  CAS  Google Scholar 

  22. Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Doi R, et al (2000) Delayed 18F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer 89:2547–2554

    Article  PubMed  CAS  Google Scholar 

  23. Nishiyama Y, Yamamoto Y, Monden T, Sasakawa Y, Tsutsui K, Wakabayashi H, et al (2005) Evaluation of delayed additional FDG PET imaging in patients with pancreatic tumour. Nucl Med Commun 26:895–901

    Article  PubMed  Google Scholar 

  24. Ruf J, Lopez Hanninen E, Oettle H, Plotkin M, Pelzer U, Stroszczynski C, et al (2005) Detection of recurrent pancreatic cancer: comparison of FDG-PET with CT/MRI. Pancreatology 5:266–272

    Article  PubMed  Google Scholar 

  25. Bares R, Klever P, Hauptmann S, Hellwig D, Fass J, Cremerius U, et al (1994) F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 192:79–86

    PubMed  CAS  Google Scholar 

  26. Keogan MT, Tyler D, Clark L, Branch MS, McDermott VG, DeLong DM, et al (1998) Diagnosis of pancreatic carcinoma: role of FDG PET. AJR Am J Roentgenol 171:1565–1570

    PubMed  CAS  Google Scholar 

  27. Kalady MF, Clary BM (2002) Clinical utility of positron emission tomography in the diagnosis and management of periampullary neoplasms. Ann Surg Oncol 9:799–806

    Article  PubMed  Google Scholar 

  28. Kato T, Fukatsu H, Ito K, Tadokoro M, Ota T, Ikeda M, et al (1995) Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problem. Eur J Nucl Med 22:32–39

    Article  PubMed  CAS  Google Scholar 

  29. Koyama K, Okamura T, Kawabe J, Nakata B, Chung KH, Ochi H, et al (2001) Diagnostic usefulness of FDG PET for pancreatic mass lesions. Ann Nucl Med 15:217–224

    PubMed  CAS  Google Scholar 

  30. Imdahl A, Reinhardt MJ, Nitzsche EU, Mix M, Dingeldey A, Einert A, et al (2000) Impact of 18F-FDG-positron emission tomography for decision making in colorectal cancer recurrences. Langenbecks Arch Surg 385:129–134

    Article  PubMed  CAS  Google Scholar 

  31. Inokuma T, Tamaki N, Torizuka T, Fujita T, Magata Y, Yonekura Y, et al (1995) Value of fluorine-18-fluorodeoxyglucose and thallium-201 in the detection of pancreatic cancer. J Nucl Med 36:229–235

    PubMed  CAS  Google Scholar 

  32. Papos M, Takacs T (2002) The possible role of F-18 FDG positron emission tomography in the differential diagnosis of focal pancreatic lesions. Clin Nucl Med 27:197–201

    Article  PubMed  Google Scholar 

  33. Rajput A, Stellato TA, Faulhaber PF, Vesselle HJ, Miraldi F (1998) The role of fluorodeoxyglucose and positron emission tomography in the evaluation of pancreatic disease. Surgery 124:793–797, discussion 797–798

    Article  PubMed  CAS  Google Scholar 

  34. Kasperk RK, Riesener KP, Wilms K, Schumpelick V (2001) Limited value of positron emission tomography in treatment of pancreatic cancer: surgeon’s view. World J Surg 25:1134–1139

    PubMed  CAS  Google Scholar 

  35. Inokuma T, Tamaki N, Torizuka T, Magata Y, Fujii M, Yonekura Y, et al (1995) Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. Radiology 195:345–352

    PubMed  CAS  Google Scholar 

  36. Koyama K, Okamura T (2001) Diagnostic usefulness of FDG PET for pancreatic mass lesions. Ann Nucl Med 15:217–224

    PubMed  CAS  Google Scholar 

  37. Valinas R, Barrier A (2002) 18 F-fluorodeoxyglucose positron emission tomography for characterization and initial staging of pancreatic tumors. Gastroenterol Clin Biol 26:888–892

    PubMed  Google Scholar 

  38. Rasmussen I, Sorensen J (2004) Is positron emission tomography using 18F-fluoro-deoxyglucose and 11C-acetate valuable in diagnosing indeterminate pancreatic masses? Scand J Surg 93:191–197

    PubMed  CAS  Google Scholar 

  39. Borbath I, Van Beers BE, Lonneux M, Schoonbroodt D, Geubel A, Gigot JF, et al (2005) Preoperative assessment of pancreatic tumors using magnetic resonance imaging, endoscopic ultrasonography, positron emission tomography and laparoscopy. Pancreatology 5:553–561

    Article  PubMed  Google Scholar 

  40. Lytras D, Connor S, Bosonnet L, Jayan R, Evans J, Hughes M, et al (2005) Positron emission tomography does not add to computed tomography for the diagnosis and staging of pancreatic cancer. Dig Surg 22:55–61

    Article  PubMed  CAS  Google Scholar 

  41. Zasadny KR, Wahl RL (1993) Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 189:847–850

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Nuklearmedizin, Universitätsklinikum Ulm, Robert-Koch-Str. 8, 89081, Ulm, Germany

    S. N. Reske

Authors
  1. S. N. Reske
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Ulm c/o University Hospital Ulm, Steinhoevelstraße 9, 89075, Ulm, Germany

    Hans G. Beger MD

  2. Department of Surgery I, Tohoku University, Medical School, 980-8574, Sendai, Japan

    Seiki Matsuno MD  & Makoto Sunamura MD, PhD  & 

  3. The Johns Hopkins University, 720 Rutland Avenue, Baltimore, MD, 21205-2196, USA

    John L. Cameron MD, PhD

  4. Department of General, Thoracic, Vascular and Transplantation Surgery, University of Rostock, Schillingallee 35, 18057, Rostock, Germany

    Bettina M. Rau MD

  5. The Sidney Kimmel Cancer Research Center, The Johns Hopkins Hospital, 1650 Orleans Street, Baltimore, MD, 21231-1000, USA

    Richard D. Schulick MD

Rights and permissions

Reprints and permissions

Copyright information

© 2008 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Reske, S.N. (2008). FDG-PET and PET/CT in Pancreatic Cancer. In: Beger, H.G., Matsuno, S., Cameron, J.L., Rau, B.M., Sunamura, M., Schulick, R.D. (eds) Diseases of the Pancreas. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-28656-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-28656-1_11

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-28655-4

  • Online ISBN: 978-3-540-28656-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation